🆕 Ya está aquí el consenso ADA/EASD 2026 sobre manejo de la diabetes tipo 2 ( regalo de Navidad adelantado 😂)
@AmDiabetesAssn@EASDnews
Pasamos de tratar la glucosa a tratar la enfermedad y sus comorbilidades.
iSGLT2 y/o GLP-1 desde el diagnóstico, con o sin metformina. Combinación precoz si ECV, ERC o IC.
Sin perder el foco en el estilo de vida! 🍎
#EASD2026
https://t.co/CV6F2fnAwy
🚨 NEW Consensus Report 🚨
Management of Type 2 Diabetes, 2026
Building on past statements, this latest report draws from studies published since 2022 to provide the latest recommendations.
Updates include:
✨A focus on holistic management
✨ Earlier use of SGLT2/GLP-1 to improve long-term outcomes
✨and more!
📚 For more, visit: https://t.co/hyfEwxOwsB
@AmDiabetesAssn@ADA_DiabetesPro@DiabetologiaJnl
📚 NOW AVAILABLE: Medical Management of Type 2 Diabetes
We're excited to announce the ninth edition of an essential clinical resource. Expert authors interpret the latest research on diagnosis and classification, management, and complications of type 2 diabetes.
This definitive update features all-new sections on hypoglycemia, obesity, and psychosocial care, as well as expanded discussions of:
✓ Diabetes education and behavior change strategies
✓ Nutrition therapy and physical activity recommendations
✓ Diabetic ketoacidosis and other acute complications
✓ Glycemic, cardiovascular, and renal benefits of pharmacological interventions
✓ Paradigm-changing diabetes technologies
In accordance with the latest Standards of Care in Diabetes, this text provides clinicians the knowledge and skills they need to ensure optimal care for people living with this complex condition.
📖 Read individual chapters online: https://t.co/hdQGM7c7Dj
🛒 Purchase your printed copy: https://t.co/z0vr9pvg9K
#DiabetesCare #MedicalReference #HealthcareProfessionals #DiabetesTreatment
How can you follow a structured approach for evaluating and managing hypomagnesaemia in community settings?
This Practice Pointer offers guidance #MedEd
https://t.co/2l5tfQv5go
The October Issue of @TheLancetEndo is now online, featuring type 1 diabetes, older adults, obesity, chronic kidney disease, type 2 diabetes, central precocious puberty, incretin therapies, endocrine-disrupting chemicals, climate change, & much more https://t.co/1LW4xvaLB1
He pagado NEJM, JAMA, The Lancet, Annals of Internal Medicine, BMJ y Nature Medicine para que tú no tengas que hacerlo.
Diariamente tendremos el resumen de artículos del día para estar al día con ellos.
¿Que opinan? 🤓🚨
"In people with type 2 #diabetes who can sustain #intermittent#fasting for at least 3–6 months, the diet is as effective for improving glycaemic control and bodyweight as caloric restriction and standard dietary advice" https://t.co/AIAu9aeCUG
#T2D#weightloss
Leqvio uses RNAi to turn down a liver protein that controls LDL recycling. By silencing PCSK9 production, it helps the body pull more LDL cholesterol out of the bloodstream via the liver. Check out my short video to see how this twice‑yearly therapy works!
https://t.co/6QF5RXnoXH